BioCentury
ARTICLE | Company News

Bioton, Medipolis deal

September 24, 2012 7:00 AM UTC

CMO Medipolis granted Bioton rights to a biosimilar insulin analog manufacturing technology. Medipolis said the deal is worth €5.3 million ($6.9 million). The companies declined to disclose details. ...